Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
BIO-B 
Bio-Rad Laboratories Inc (BIO-B)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: BIO-B (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -32.23% | Avg. Invested days 13 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 6.73B USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 125 | Beta 0.98 | 52 Weeks Range 241.99 - 373.35 | Updated Date 04/2/2025 |
52 Weeks Range 241.99 - 373.35 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -65.36 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -71.86% | Operating Margin (TTM) 8.68% |
Management Effectiveness
Return on Assets (TTM) 1.55% | Return on Equity (TTM) -24.09% |
Valuation
Trailing PE - | Forward PE 26.32 | Enterprise Value 6442964050 | Price to Sales(TTM) 2.62 |
Enterprise Value 6442964050 | Price to Sales(TTM) 2.62 | ||
Enterprise Value to Revenue 2.51 | Enterprise Value to EBITDA -13.07 | Shares Outstanding 5070340 | Shares Floating 20420963 |
Shares Outstanding 5070340 | Shares Floating 20420963 | ||
Percent Insiders 98.05 | Percent Institutions 0.08 |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Bio-Rad Laboratories Inc
Company Overview
History and Background
Bio-Rad Laboratories Inc. was founded in 1952 in Berkeley, California. Initially focused on supplying research products, it has grown to become a global leader in life science research and clinical diagnostics. The company has expanded through organic growth and strategic acquisitions.
Core Business Areas
- Clinical Diagnostics: Provides in vitro diagnostic products and systems that automate and support clinical laboratories in hospitals, reference labs, and physician office settings. Products include quality controls, instrument systems, and assays for blood typing, diabetes monitoring, autoimmune diagnostics, infectious disease testing, and clinical immunology.
- Life Science: Develops, manufactures, and markets a wide range of instruments, reagents, and software used to separate, purify, identify, analyze, and amplify biological materials such as antibodies, proteins, nucleic acids, cells, and bacteria. It offers solutions for genomics, proteomics, cell biology, food safety, and bioprocessing.
Leadership and Structure
The company is led by Norman Schwartz (Chairman & CEO). Bio-Rad operates with a functional organizational structure across its business segments.
Top Products and Market Share
Key Offerings
- Quality Controls: Bio-Rad offers a broad range of quality controls for clinical diagnostics, ensuring the accuracy and reliability of laboratory tests. This is a critical aspect of clinical lab operations. Competitors include Roche Diagnostics and Abbott Diagnostics. Bio-Rad has a strong presence in the quality controls market, estimated around 15-20% market share in specific segments. Revenue is a consistent and significant contributor to the Clinical Diagnostics revenue.
- ddPCR (Droplet Digital PCR) Systems: Bio-Rad's Droplet Digital PCR (ddPCR) technology allows for highly precise and sensitive quantification of nucleic acids. This is widely used in cancer research, gene therapy, and liquid biopsy. Competitors include Thermo Fisher Scientific (QuantStudio Digital PCR) and Qiagen (QIAcuity Digital PCR). Market share is estimated around 25-30% in the digital PCR market. Revenue from ddPCR is a significant portion of the Life Science segment's revenue.
Market Dynamics
Industry Overview
The life science and clinical diagnostics industries are experiencing growth due to technological advancements, increasing healthcare spending, and aging populations. Personalized medicine and molecular diagnostics are key growth areas.
Positioning
Bio-Rad is positioned as a leading provider of innovative tools and technologies for life science research and clinical diagnostics. Its strengths include a strong brand reputation, a broad product portfolio, and a global distribution network.
Total Addressable Market (TAM)
The combined TAM for life science tools and clinical diagnostics is estimated to be over $100 billion. Bio-Rad is positioned to address a significant portion of this TAM through its diverse product offerings.
Upturn SWOT Analysis
Strengths
- Strong brand recognition
- Broad product portfolio
- Global distribution network
- Innovative technology platforms
- Large customer base in both research and diagnostics
Weaknesses
- Susceptibility to currency fluctuations
- High research and development costs
- Dependence on key suppliers
- Complexity of regulatory environment
Opportunities
- Expanding into emerging markets
- Developing new diagnostic assays
- Acquiring complementary technologies
- Increasing adoption of personalized medicine
- Growing demand for bioprocessing solutions
Threats
- Increasing competition
- Price pressures
- Regulatory changes
- Economic downturns
- Technological obsolescence
Competitors and Market Share
Key Competitors
- TMO
- DHR
- PKI
- LRCX
Competitive Landscape
Bio-Rad competes with larger, diversified companies. Its advantages lie in its specialized expertise and innovative technologies, while its disadvantages include its smaller size and limited resources compared to some competitors.
Major Acquisitions
Exact Diagnostics
- Year: 2019
- Acquisition Price (USD millions): 145
- Strategic Rationale: Expanded Bio-Rad's quality control offerings in the clinical diagnostics market.
Growth Trajectory and Initiatives
Historical Growth: Bio-Rad has historically grown through both organic expansion and strategic acquisitions.
Future Projections: Future growth projections are based on analyst estimates and can be found on financial news platforms.
Recent Initiatives: Recent initiatives have focused on expanding the ddPCR portfolio and developing new diagnostic assays.
Summary
Bio-Rad is a well-established company in the life science and clinical diagnostics industries with a strong brand and a broad product portfolio. The company's innovative technologies, particularly in ddPCR and quality controls, are key strengths. Bio-Rad faces competition from larger players and must navigate a complex regulatory environment. Continued focus on innovation and strategic acquisitions will be crucial for maintaining its growth trajectory.
Similar Companies
DHR
Danaher Corporation
DHR
Danaher Corporation
ILMN
Illumina Inc
ILMN
Illumina Inc
LRCX
Lam Research Corp
LRCX
Lam Research Corp
TMO
Thermo Fisher Scientific Inc
TMO
Thermo Fisher Scientific Inc
Sources and Disclaimers
Data Sources:
- Company website (investor relations)
- Financial news sources
- Industry reports
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered financial advice. Market share estimates are approximate and based on publicly available information. Financial performance data requires accessing up to date financial databases
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Bio-Rad Laboratories Inc
Exchange NYSE | Headquaters Hercules, CA, United States | ||
IPO Launch date 1999-09-21 | Chairman & CEO Mr. Norman D. Schwartz | ||
Sector Healthcare | Industry Medical Devices | Full time employees 7700 | Website https://www.bio-rad.com |
Full time employees 7700 | Website https://www.bio-rad.com | ||
Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials, such as cells, proteins, and nucleic acids used in biopharmaceutical manufacturing, quality control process, food safety, and science education applications. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, and transfusion and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.